Last reviewed · How we verify
Pro-biotics
Pro-biotics is a Probiotic Small molecule drug developed by National Cheng-Kung University Hospital. It is currently FDA-approved for Gastrointestinal health maintenance, Antibiotic-associated diarrhea prevention, Digestive support and microbiome restoration.
Probiotics restore and maintain beneficial bacterial flora in the gastrointestinal tract to support digestive health and immune function.
Probiotics are a type of intervention studied in various clinical trials, including those examining their effects on conditions such as peritonitis, malnutrition, and the human gut microbiota. Probiotics are a protein-based modality, according to ChEMBL, and have been tested in combination with other interventions in trials such as NCT06931977.
At a glance
| Generic name | Pro-biotics |
|---|---|
| Sponsor | National Cheng-Kung University Hospital |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Probiotics are live microorganisms that colonize the gut microbiome, competing with pathogenic bacteria, producing short-chain fatty acids, and strengthening the intestinal barrier. They enhance immune tolerance through interaction with gut-associated lymphoid tissue and promote nutrient absorption and metabolism. These mechanisms help prevent gastrointestinal infections, reduce inflammation, and support overall digestive wellness.
Approved indications
- Gastrointestinal health maintenance
- Antibiotic-associated diarrhea prevention
- Digestive support and microbiome restoration
Common side effects
- Mild gastrointestinal symptoms (bloating, gas)
- Allergic reactions (rare)
Key clinical trials
- Natural Product System and Lifestyle Modification (NA)
- Biotics Intervention Oriented to Rescue From Environmental Pollution Inflammatory Responses (NA)
- Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women (NA)
- Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism (NA)
- Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota (NA)
- Probiotics Use in the Chronic Peritoneal Dialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pro-biotics CI brief — competitive landscape report
- Pro-biotics updates RSS · CI watch RSS
- National Cheng-Kung University Hospital portfolio CI
Frequently asked questions about Pro-biotics
What is Pro-biotics?
How does Pro-biotics work?
What is Pro-biotics used for?
Who makes Pro-biotics?
What drug class is Pro-biotics in?
What development phase is Pro-biotics in?
What are the side effects of Pro-biotics?
Related
- Drug class: All Probiotic drugs
- Manufacturer: National Cheng-Kung University Hospital — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastrointestinal health maintenance
- Indication: Drugs for Antibiotic-associated diarrhea prevention
- Indication: Drugs for Digestive support and microbiome restoration
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing